A multi-billion buyout by Merck of pharma company Acceleron Pharma will lead to 143 job losses.
Merck completed the £11.5 billion acquisition of the company last November, which has led to lay-offs of existing Acceleron staff, based in Cambridge, Massachusetts.
A Merck spokesperson said: “On Tuesday, March 15, Merck issued a Worker Adjustment and Retraining Notification Act (“WARN”) notice to 143 legacy employees of Acceleron Pharma who will be separating from the company in a phased manner through Friday, November 18, 2022, around the time of the acquisition, employees were either offered a full-time role or were asked to remain to support the integration for a defined period of time. “
READ MORE: MASSACHUSETTS BIOTECHNOLOGY COMPANY ANNOUNCES JOB CUTS
“As part of the ongoing integration of Acceleron, we have extended more than 160 offers since November 2021, of which 75% have accepted positions since the acquisition was announced.”
